Featured Research

from universities, journals, and other organizations

Adult stem cells help build human blood vessels in engineered tissues

Date:
October 14, 2013
Source:
University of Illinois at Chicago
Summary:
Researchers have identified a protein expressed by human bone marrow stem cells that guides and stimulates the formation of blood vessels. Their findings could help improve the vascularization of engineered tissues.

Jalees Rehman, associate professor of cardiology and pharmacology.
Credit: Image courtesy of University of Illinois at Chicago

Researchers at the University of Illinois at Chicago have identified a protein expressed by human bone marrow stem cells that guides and stimulates the formation of blood vessels.

Their findings, which could help improve the vascularization of engineered tissues, were reported online on October 12 in the Journal of Molecular and Cellular Cardiology.

"Some stem cells actually have multiple jobs," says Dr. Jalees Rehman, associate professor of cardiology and pharmacology at the UIC College of Medicine and lead author of the paper. For example, stem cells in the bone marrow, he said, differentiate into bone or cartilage, but also have a secondary role in helping to support other cells in the bone marrow.

Rehman and his colleagues, who are developing engineered tissues for use in cardiac patients, observed that certain stem cells in bone marrow, called mesenchymal stem cells, seemed crucial for organizing other cells into functional blood vessels.

The researchers demonstrated that when they mixed mesenchymal stem cells from human bone marrow with the endothelial cells that line blood vessels, the stem cells elongated to form scaffolds and the endothelial cells organized around them to form tubes.

"But without the stem cells, the endothelial cells just sat there," said Rehman.

When the cell mixtures were implanted into mice, blood vessels formed that were able to support the flow of blood. To find out how the stem cells were helping promote blood vessel formation, the researchers looked at which genes were being expressed when the stem cells and endothelial cells were combined.

They tested two different stem cell lines from human bone marrow. One line supported the formation of blood vessel networks when it was mixed with endothelial cells, while the other cell line did not.

They analyzed the genetic signature and proteins of the respective cell lines and found that the vessel-supporting stem cell line released high levels of a blood vessel guidance molecule -- SLIT3. In the mixture that didn't form blood vessels, the SLIT3 gene was hardly expressed, Rehman said.

"This means that not all stem cells are created alike in terms of their SLIT3 production and their ability to encourage blood vessel formation," Rehman said. "While using a patient's own stem cells for making blood vessels is ideal because it eliminates the problem of immune rejection, it might be a good idea to test a patient's stem cells first to make sure they are good producers of SLIT3. If they aren't, the engineered vessels may not thrive, or even fail to grow."

Mesenchymal stem cell injections are currently being evaluated in clinical trials to see if they can help grow blood vessels and improve heart function in patients who have suffered heart attacks. So far, the benefits of stem cell injection have been modest, Rehman said. "Evaluating the gene and protein signatures of stem cells from each patient may allow for a more individualized approach, so that every patient receives mesenchymal stem cells that are most likely to promote blood vessel growth and cardiac repair. Hopefully, this will substantially increase the efficacy of stem cell treatments for heart patients." An extended interview as MP3 audio file.

Co-authors on the research publication are Jonathan Paul and Vytas Bindokas of the University of Chicago Pritzker School of Medicine; Kareen Coulombe, David Smith and Charles Murry at the University of Washington, and Peter Toth, Yanmin Zhang and Glenn Marsboom of UIC.

This research was funded by grants from the National Institutes of Health (R01-GM094220, K08-HL080082, RO1-HL084642, P01-HL094374, P01-GM81619, U01-HL100405, T32-HL007381, T32-HL007312) and by the Heart Research Foundation.


Story Source:

The above story is based on materials provided by University of Illinois at Chicago. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jonathan D. Paul, Kareen L.K. Coulombe, Peter T. Toth, Yanmin Zhang, Glenn Marsboom, Vytas P. Bindokas, David W. Smith, Charles E. Murry, Jalees Rehman. SLIT3–ROBO4 activation promotes vascular network formation in human engineered tissue and angiogenesis in vivo. Journal of Molecular and Cellular Cardiology, 2013; 64: 124 DOI: 10.1016/j.yjmcc.2013.09.005

Cite This Page:

University of Illinois at Chicago. "Adult stem cells help build human blood vessels in engineered tissues." ScienceDaily. ScienceDaily, 14 October 2013. <www.sciencedaily.com/releases/2013/10/131014113739.htm>.
University of Illinois at Chicago. (2013, October 14). Adult stem cells help build human blood vessels in engineered tissues. ScienceDaily. Retrieved July 21, 2014 from www.sciencedaily.com/releases/2013/10/131014113739.htm
University of Illinois at Chicago. "Adult stem cells help build human blood vessels in engineered tissues." ScienceDaily. www.sciencedaily.com/releases/2013/10/131014113739.htm (accessed July 21, 2014).

Share This




More Health & Medicine News

Monday, July 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins